Business
Cognition Therapeutics Presents Phase 2 Results For Drug To Fight DLB At International Conference
--News Direct--By Meg Flippin, BenzingaCognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative
About this update from Cognition Therapeutics, Inc.
[{"type":"text","content":"--News Direct--By Meg Flippin, BenzingaCognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders including dementia with Lewy bodies (DLB), had the opportunity to raise awareness about its experimental drug zervimesine (CT1812) when the company presented trial results in a podium presentation at the International Lewy Body Dementia Conference (ILBDC). The eighth International Lewy Body Dementia Conference, held in Amsterdam last week, drew an international audience of advocates, scientists and physicians looking for ways to fight this debilitating disease. Zervimesine is an experimental, orally delivered small molecule oligomer antagonist designed to treat this progressive form of dementia. Cognition Therapeutics recently reported positive topline results of its exploratory phase 2 SHIMMER study for the drug, announcing zervimesine produced strong therapeutic responses across behavioral, functional, cognitive and movement measures in patients with DLB. “Older adults with DLB are often placed in care facilities not because of memory issues, but due to the severity of neuropsychiatric or motor symptoms that overwhelm their caregivers,” said James E. Galvin, MD, MPH, director of the Comprehensive Center for Brain Health at the University of Miami Miller School of Medicine, who was the study director for SHIMMER . “Patients on zervimesine had fewer cognitive fluctuations and showed better motor control than placebo-treated patients. The results from this exploratory phase 2 trial demonstrated zervimesine could have a meaningful, positive impact on DLB patients across multiple measures of cognitive, behavioral, movement and functional performance, potentially enabling people with DLB to live at home with the assistance of their care partners.”DLB Drug Holds PromiseDLB is a progressive form of dementia characterized by symptoms that fluctuate in severity and can be difficult to diagnose early. It can cause people to have hallucinations, delusions and anxiety as well as cognitive declines that impair their thinking and reasoning. It can cause uncontrollable changes in alertness, sleep disruptions, tremors and slow movement. DLB impacts about 1.4 million people in the U.S. and is the costliest form of dementia.The double-blind, placebo-controlled phase 2 SHIMMER study h...